191 related articles for article (PubMed ID: 16787349)
1. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate.
Blake JF
Med Chem; 2005 Nov; 1(6):649-55. PubMed ID: 16787349
[TBL] [Abstract][Full Text] [Related]
2. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
3. [Strategy of molecular drug design: hits, leads and drug candidates].
Guo ZR
Yao Xue Xue Bao; 2008 Sep; 43(9):898-904. PubMed ID: 19048779
[TBL] [Abstract][Full Text] [Related]
4. Lead-oriented synthesis: a new opportunity for synthetic chemistry.
Nadin A; Hattotuwagama C; Churcher I
Angew Chem Int Ed Engl; 2012 Jan; 51(5):1114-22. PubMed ID: 22271624
[TBL] [Abstract][Full Text] [Related]
5. Solubility and permeability measurement and applications in drug discovery.
Burton PS; Goodwin JT
Comb Chem High Throughput Screen; 2010 Feb; 13(2):101-11. PubMed ID: 20053165
[TBL] [Abstract][Full Text] [Related]
6. Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space.
Meanwell NA
Chem Res Toxicol; 2016 Apr; 29(4):564-616. PubMed ID: 26974882
[TBL] [Abstract][Full Text] [Related]
7. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
[TBL] [Abstract][Full Text] [Related]
8. Chemistry challenges in lead optimization: silicon isosteres in drug discovery.
Showell GA; Mills JS
Drug Discov Today; 2003 Jun; 8(12):551-6. PubMed ID: 12821303
[TBL] [Abstract][Full Text] [Related]
9. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
[TBL] [Abstract][Full Text] [Related]
10. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges.
Masimirembwa CM; Bredberg U; Andersson TB
Clin Pharmacokinet; 2003; 42(6):515-28. PubMed ID: 12793837
[TBL] [Abstract][Full Text] [Related]
11. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
[TBL] [Abstract][Full Text] [Related]
12. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
13. Structure-based screening and design in drug discovery.
van Dongen M; Weigelt J; Uppenberg J; Schultz J; Wikström M
Drug Discov Today; 2002 Apr; 7(8):471-8. PubMed ID: 11965396
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery today.
Schwardt O; Kolb H; Ernst B
Curr Top Med Chem; 2003; 3(1):1-9. PubMed ID: 12570684
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive assessment of ADMET risks in drug discovery.
Wang J
Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in physicochemical and ADMET profiling in drug discovery.
Wang J; Skolnik S
Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
[TBL] [Abstract][Full Text] [Related]
17. Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research?
Beaumont K; Smith DA
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):61-71. PubMed ID: 19152214
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in computational prediction of drug absorption and permeability in drug discovery.
Hou T; Wang J; Zhang W; Wang W; Xu X
Curr Med Chem; 2006; 13(22):2653-67. PubMed ID: 17017917
[TBL] [Abstract][Full Text] [Related]
19. New screening tools for lead compound identification.
Sawyer TK
Nat Chem Biol; 2005 Aug; 1(3):125. PubMed ID: 16408012
[No Abstract] [Full Text] [Related]
20. Modelling of the blood-brain barrier in drug discovery and development.
Cecchelli R; Berezowski V; Lundquist S; Culot M; Renftel M; Dehouck MP; Fenart L
Nat Rev Drug Discov; 2007 Aug; 6(8):650-61. PubMed ID: 17667956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
